Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Castleark Management LLC

Castleark Management LLC cut its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 13.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,990 shares of the biotechnology company's stock after selling 5,450 shares during the period. Castleark Management LLC owned about 0.05% of Blueprint Medicines worth $3,144,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BPMC. Amalgamated Bank raised its holdings in shares of Blueprint Medicines by 5.3% in the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company's stock worth $232,000 after acquiring an additional 109 shares during the last quarter. Van ECK Associates Corp raised its stake in Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $120,000 after purchasing an additional 131 shares during the last quarter. EFG Asset Management North America Corp. boosted its stake in shares of Blueprint Medicines by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company's stock worth $3,008,000 after purchasing an additional 132 shares during the last quarter. Pallas Capital Advisors LLC grew its holdings in shares of Blueprint Medicines by 3.2% during the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company's stock worth $523,000 after buying an additional 176 shares in the last quarter. Finally, Clarus Wealth Advisors raised its position in shares of Blueprint Medicines by 8.6% in the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company's stock valued at $231,000 after buying an additional 206 shares during the last quarter.

Blueprint Medicines Stock Up 0.9 %

Shares of BPMC stock traded up $0.89 during trading hours on Friday, reaching $95.97. The company had a trading volume of 373,649 shares, compared to its average volume of 556,725. The company has a market capitalization of $6.10 billion, a P/E ratio of -45.48 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. Blueprint Medicines Co. has a twelve month low of $71.97 and a twelve month high of $121.90. The stock's fifty day simple moving average is $91.62 and its 200 day simple moving average is $97.79.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business's quarterly revenue was up 126.5% on a year-over-year basis. During the same quarter last year, the firm posted ($2.20) earnings per share. As a group, sell-side analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. UBS Group started coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a "neutral" rating and a $88.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Thursday, November 14th. JPMorgan Chase & Co. began coverage on Blueprint Medicines in a research report on Thursday, November 14th. They set an "overweight" rating and a $126.00 target price on the stock. Wells Fargo & Company decreased their price target on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating on the stock in a research note on Thursday, October 31st. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.11.

Insiders Place Their Bets

In other Blueprint Medicines news, CEO Kate Haviland sold 2,353 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $96.60, for a total value of $227,299.80. Following the transaction, the chief executive officer now directly owns 150,824 shares of the company's stock, valued at $14,569,598.40. This represents a 1.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares of the company's stock, valued at approximately $6,814,580.70. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,260 shares of company stock worth $768,057 in the last quarter. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.